Machine-Learning Identifies a Strategy for Differentiation Therapy in Solid Tumors

Author:

Sinha Saptarshi,Alcantara Joshua,Perry Kevin,Castillo Vanessa,Espinoza Celia R.,Taheri Sahar,Vidales Eleadah,Tindle Courtney,Adel Adel,Amirfakhri Siamak,Sawires Joseph R.,Yang Jerry,Bouvet Michael,Sahoo Debashis,Ghosh Pradipta

Abstract

AbstractBackgroundAlthough differentiation therapy can ‘cure’ some hematologic malignancies, its curative potential remains unrealized in solid tumors. This is because conventional computational approaches succumb to the thunderous noise of inter-/intratumoral heterogeneity. Using colorectal cancers (CRCs) as an example, here we outline a machine learning(ML)-based approach to track, differentiate, and selectively target cancer stem cells (CSCs).MethodsA transcriptomic network was built and validated using healthy colon and CRC tissues in diverse gene expression datasets (∼5,000 human and >300 mouse samples). Therapeutic targets and perturbation strategies were prioritized using ML, with the goal of reinstating the expression of a transcriptional identifier of the differentiated colonocyte, CDX2, whose loss in poorly differentiated (CSC-enriched) CRCs doubles the risk of relapse/death. The top candidate target was then engaged with a clinical-grade drug and tested on 3 models: CRC linesin vitro, xenografts in mice, and in a prospective cohort of healthy (n = 3) and CRC (n = 23) patient-derived organoids (PDOs).ResultsThe drug shifts the network predictably, inducesCDX2and crypt differentiation, and shows cytotoxicity in all 3 models, with a high degree of selectivity towards allCDX2-negative cell lines, xenotransplants, and PDOs. The potential for effective pairing of therapeutic efficacy (IC50) and biomarker (CDX2-low state) is confirmed in PDOs using multivariate analyses. A 50-gene signature of therapeutic response is derived and tested on 9 independent cohorts (∼1700 CRCs), revealing the impact ofCDX2-reinstatement therapy could translate into a ∼50% reduction in the risk of mortality/recurrence.ConclusionsFindings not only validate the precision of the ML approach in targeting CSCs, and objectively assess its impact on clinical outcome, but also exemplify the use of ML in yielding clinical directive information for enhancing personalized medicine.

Publisher

Cold Spring Harbor Laboratory

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3